FG Cardio COMPLETE

Pharmacogenetics in Cardiology

SYNLAB SOLUTIONS IN DIAGNOSTICS

www.synlanb-sd.com





Why undergoing this examination?

Cardiovascular diseases encompass a set of pathologies related to the heart and blood vessels, which can occur due to genetic as well as environmental factors. Among the related cardiovascular and metabolic diseases, notable ones include hyperlipidemia, arterial hypertension, diabetes mellitus, coagulation disorders, and arrhythmias.

The pharmacological treatment of cardiovascular diseases is based on the use of various medications aimed at alleviating both the causes and symptoms of the disease.

Even with recent advances in pharmacological treatment, not all patients with cardiovascular diseases respond adequately to medication. Human genome variation is one of the most important factors responsible for modulating the individual response to pharmacological treatment.

What is the exam?

The **FG Cardio Complete** pharmacogenetic panel evaluates the main metabolizing enzymes and targets involved in the effect and toxicity of different drugs used in the treatment of cardiovascular diseases, providing the ability to select the most suitable drug and individually guide the dose for each patient.

For whom is it indicated?

- Patients with cardiovascular diseases who want to personalize treatment based on their genetic profile;
- Patients with cardiovascular diseases for whom pharmacological treatment does not yield expected results.

Technology

Next-generation sequencing (NGS).

Advantages

SYNLAB GROUP

Guaranteed by the experience of the absolute European leader in laboratory diagnostics.

COMPLETE

Detailed report, including the type of metabolism of each enzyme, which drugs may cause toxic effects and adverse reactions, as well as recommendations on doses.

Extra Information

DOCUMENTATION - Available on the SYNLAB Direct for clients

- Informed Consent;
- Clinical Questionnaire;
- Medical Request.

PREPARATION

• Fasting is not necessary for the exam.



Delivery Time 22 business days



Sample Type

5 mL of whole blood in EDTA

Additional Information

	Studied Drugs	
Acenocoumarol	Enalapril (P)	Metoprolol
A.A.S	Eplerenone	
Aliskiren	Eprosartan	Nebivolol
Amiodarone	Spironolactone	Nifedipine
Amlodipine (P)	Ezetimibe	Olmesartan
Apixaban	Felodipine	Perindopril
Atenolol	Fenofibrate (P)	Propafenone
Atorvastatin	Flecainide	Propranolol
Bisoprolol	Fosinopril (P)	Ramipril
Candesartan	Hydrochlorothiazide	Ranolazine
Captopril	Irbesartan	Rivaroxaban
Carvedilol	lyabradine	Rosuvastatin
Clopidogrel	Lercanidipine	Sinvastatin
		Telmisartan
Chlorthalidone	Lisinopril	Torasemide
Digoxin	Losartan (P)	Valsartan
Diltiazem	Lovastatin	Warfarin
Doxazosin	Manidipine	Verapamil
Dronedarone		

Dronedarone

(P): Prodrug. A pharmacologically inactive or weakly active substance administered in an inactive form. The prodrug is metabolized in the body to an active metabolite.

www.synlab-sd.com